Nötropenik Ateşli Hastaya Yaklaşım

Authors

Ferhat Bingöl

Synopsis

Neutropenic fever is a clinical emergency characterized by a body temperature above 38°C when the absolute neutrophil count falls below 500/mm³. Although an infectious focus is often not identified, common origins include bloodstream, respiratory tract, catheter, and mucosal infections. Bacteria represent the most frequent pathogens (70-90%), with Staphylococcus epidermidis being the most predominant gram-positive organism. Patient evaluation relies on detailed physical examination, blood cultures, and the MASCC risk index, where a score above 21 indicates low risk and below 21 signals high risk. Due to the rapid progression of infections, broad-spectrum empirical antibiotic therapy must be initiated within one hour. Low-risk patients can be managed in an outpatient setting using oral quinolone-based regimens, whereas high-risk patients require hospitalization for IV monotherapy (e.g., cefepime, piperacillin/tazobactam) or combination therapies. Glycopeptides are added under specific conditions such as suspected catheter-related infections or hemodynamic instability. Antifungal or antiviral agents are incorporated into the regimen if fever persists or specific pathogens are suspected. Finally, strict environmental precautions, including meticulous hand hygiene and proper isolation protocols, are essential to prevent cross-contamination and nosocomial infections.

References

Hughes WT, Armstrong D, Bodey GP. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730-51.

Alison G. Freifeld, Eric J. Bow, Kent A. Sepkowitz, et al. Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America, Clinical Infectious Diseases. 2011;52(4): e56–e93

Febril nötropeni çalışma grubu. Febril nötropenik hastalarda tanı ve tedavi kılavuzu. Flora 2004; 9: 5-28.

Marin M, Gudiol C, Ardanuy C, et al. Bloodstream infections in neutropenic patients with cancer: Differences between patients with haematological malignancies and solid tumours. J Infect 2014; 69(5):417-23.

Pagano L, Caira M, Nosari A, et al. Etiology of febrile episodes in patients witch acute meloid leukemia: results fom the Hema e Chart Registry. Arch Intern Med 2011; 171: 1502.

Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J; ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016 Sep; 27(suppl 5):v111-v118.

Klastersky J Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Canser risk indesx: Amultinational scoring system for identifying low-risk febrile neutropenic canser patiens, J Clin Oncol 2000; 18:3038.

Walter T. Hughes, Donald Armstrong, Gerald P. Bodey, et al. 2002 Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer, Clinical Infectious Diseases. 2002;34(6):730-51

Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011 15; 52(4):56-93.

Averbuch D, Orasch C, Cordonnier C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013; 98(12):1826-1835.

Published

May 20, 2021

License

License